AK
AKTS.O
—
NASDAQ
Biotechnology
Aktis Oncology Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-1 149,5 %
ROE
-34,0 %
Net margin
-980,9 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$24,01
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Aktis Oncology Inc is a biotechnology company operating in the Health Care sector, focused on oncology research and development.
Business. Aktis Oncology Inc (AKTS.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-34,0 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to AKTS.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Aktis Oncology Inc (AKTS.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDAktis Oncology Inc maintains a debt-free capital structure with zero long-term debt and a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $264.9 million against total liabilities of $77.6 million, resulting in total equity of $187.3 million. Liquidity is robust, evidenced by a current ratio of 7.37 and cash and equivalents of $37.8 million. However, the company is cash-burn intensive, with operating cash flow at -$64.1 million and free cash flow at -$70.9 million for the latest period.
Profitability metrics reflect the pre-commercial stage of the business. Net income stands at -$63.7 million, leading to a return on equity of -34.03% and a return on assets of -24.06%. Operating income is negative at -$74.7 million. Revenue is minimal at $6.5 million, indicating that the company is not yet generating significant commercial sales to offset its research and development and operational expenses.
Key takeaways
- Debt-free balance sheet with $187.3 million in equity and a 7.37 current ratio.
- Significant cash burn with -$70.9 million in free cash flow and -$63.7 million net income.
- Minimal revenue of $6.5 million indicates pre-commercial or early-commercial stage.
- Low dilution risk with no difference between basic and diluted share counts.
- No historical trend data available to assess revenue growth momentum.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$22,23
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$187.3M
Net cashⓘ
$37.8M
Current ratioⓘ
7.4
Debt / equityⓘ
0.0
ROAⓘ
-24.1%
ROEⓘ
-34.0%
Cash conversionⓘ
101.0%
CapEx / revenueⓘ
-1.5%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution7 analysts
Strong buy4
Buy3
Hold0
Sell0
Strong sell0
12-month price target$35,50 · Median $34,50
Low $33,00High $40,00
Operating income · consensus-103,4M USD
EPS surprise
−4 463,5 %
reported vs consensus · miss
Revenue surprise
−61,4 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$33,00
Mean$35,50
Median$34,50
High$40,00
Spot$22,23
+59.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-1 149,5 %Bottom quartile
Net Margin-980,9 %Bottom quartile
ROE-34,0 %Below median
Capex / Rev-147,5 %Bottom quartile
D/E0,00Above median
Cash Conv1,01Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 34 294 046 sh5 exercises · 1 grants11 insiders
- Director · Stock Option (Right to Buy) → Common StockDisposed 3 506 @ $0,08exercise · 2026-07-20
- Director · Stock Option (Right to Buy) → Common StockDisposed 1 350 @ $1,91exercise · 2026-07-20
- Director · Stock Option (Right to Buy) → Common StockDisposed 3 065 @ $0,08exercise · 2026-07-17
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 50 000 @ $3,66exercise · 2026-07-08
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 50 000 @ $4,95exercise · 2026-07-08
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 866 @ $18,09grant · 2026-04-15
- Director, 10% owner · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 716 872conversion · 2026-01-12
- Director · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 26 942conversion · 2026-01-12
- Director · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 6 489conversion · 2026-01-12
- Director, 10% owner · Series Seed Redeemable Convertible Preferred Stock → Common StockDisposed 597 391conversion · 2026-01-12
- Director, 10% owner · Series A Redeemable Convertible Preferred Stock → Common StockDisposed 2 688 270conversion · 2026-01-12
- 10% owner · Series Seed Redeemable Convertible Preferred Stock → Common StockDisposed 1 314 262conversion · 2026-01-12
- 10% owner · Series Seed Redeemable Convertible Preferred Stock → Common StockDisposed 1 314 262conversion · 2026-01-12
- 10% owner · Series A Redeemable Convertible Preferred Stock → Common StockDisposed 5 914 197conversion · 2026-01-12
- 10% owner · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 1 577 119conversion · 2026-01-12
- Director, 10% owner · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 959 086conversion · 2026-01-12
- Director, 10% owner · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 26 613conversion · 2026-01-12
- Director · Series A Redeemable Convertible Preferred Stock → Common StockDisposed 13 142conversion · 2026-01-12
- 10% owner · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 1 577 119conversion · 2026-01-12
- Director · Series A Redeemable Convertible Preferred Stock → Common StockDisposed 2 605 878conversion · 2026-01-12
- 10% owner · Series A Redeemable Convertible Preferred Stock → Common StockDisposed 5 914 197conversion · 2026-01-12
- Director · Series A Redeemable Convertible Preferred Stock → Common StockDisposed 262 142conversion · 2026-01-12
- Director · Series A Redeemable Convertible Preferred Stock → Common StockDisposed 128 506conversion · 2026-01-12
- Director · Series B Redeemable Convertible Preferred Stock → Common StockDisposed 630 191conversion · 2026-01-12
- Director · Class A Common Stock → Common StockAcquired 86 222conversion · 2026-01-12
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Equitynet_income / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
Source documents
- Aktis Oncology Inc Market data — financials · 2026-07-26
- reconciler_enqueue (reconciler) on AKTS.O · 2026-07-26
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,03 %$0M
- Institutional Investor · as of 2026-03-310,01 %$26M
- Investment Managers · as of 2026-03-310,01 %$41M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$8M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Leadership
- Matthew RodenPresident, Chief Executive Officer, Director
Insider activity
Net buying9 buys · 9 sellsnet $111,3M10 insiders · last 365d
- Director · Common StockSold 3 506 @ $24,56$86K · 2026-07-20
- Director · Common StockSold 1 350 @ $24,56$33K · 2026-07-20
- Director · Common StockOther 1 350 @ $1,91$3K · 2026-07-20
- Director · Common StockOther 3 506 @ $0,08$280 · 2026-07-20
- Director · Common StockSold 3 065 @ $25,21$77K · 2026-07-17
- Director · Common StockOther 3 065 @ $0,08$245 · 2026-07-17
- Chief Operating Officer · Common StockSold 30 000 @ $27,94$838K · 2026-07-08
- Chief Medical Officer · Common StockSold 4 371 @ $28,71$125K · 2026-07-08
- Chief Medical Officer · Common StockSold 30 829 @ $27,95$862K · 2026-07-08
- Chief Medical Officer · Common StockSold 14 800 @ $27,13$401K · 2026-07-08
- Chief Operating Officer · Common StockOther 50 000 @ $3,66$183K · 2026-07-08
- Chief Operating Officer · Common StockSold 15 800 @ $27,13$429K · 2026-07-08
- Chief Operating Officer · Common StockSold 4 200 @ $28,75$121K · 2026-07-08
- Chief Medical Officer · Common StockOther 50 000 @ $4,95$248K · 2026-07-08
- Director, 10% owner · Common StockBought 232 870 @ $18,00$4,2M · 2026-01-12
- 10% owner · Common StockOther 1 577 119 · 2026-01-12
- 10% owner · Common StockOther 5 914 197 · 2026-01-12
- 10% owner · Common StockOther 1 314 262 · 2026-01-12
- 10% owner · Common StockBought 1 112 777 @ $18,00$20,0M · 2026-01-12
- 10% owner · Common StockOther 1 577 119 · 2026-01-12
- 10% owner · Common StockOther 5 914 197 · 2026-01-12
- 10% owner · Common StockOther 1 314 262 · 2026-01-12
- 10% owner · Common StockBought 1 112 777 @ $18,00$20,0M · 2026-01-12
- Director, 10% owner · Common StockOther 716 872 · 2026-01-12
- Director, 10% owner · Common StockOther 2 688 270 · 2026-01-12
Short positioning
3.7Mshares short+13.1% vs prior
6.26days to cover
36.2%short of daily vol
757fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
AKTS.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Shares outstanding (annual): 915.26KUnknown
- Cash & equivalents (annual): USD 37.78MUnknown
- Total liabilities (annual): USD 77.62MUnknown
- Current assets (annual): USD 230.31MUnknown
- Total assets (annual): USD 264.88MUnknown
- Current liabilities (annual): USD 31.24MUnknown
- Shareholders' equity (annual): USD -146.15MUnknown
- Shareholders' equity (annual): USD -87.8MUnknown
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-20INSIDERHerrmann Ken transacted 1.4k sh — Director ~$3k
2026-07-20INSIDERHerrmann Ken transacted 3.5k sh — Director ~$0k
2026-07-20INSIDERHerrmann Ken sold 3.5k sh — Director ~$86k
2026-07-20INSIDERHerrmann Ken sold 1.4k sh — Director ~$33k
2026-07-20INSIDERHerrmann Ken disposed of 1.4k sh Stock Option (Right to Buy) — Director
2026-07-20INSIDERHerrmann Ken disposed of 3.5k sh Stock Option (Right to Buy) — Director
2026-07-17INSIDERHerrmann Ken transacted 3.1k sh — Director ~$0k
2026-07-17INSIDERHerrmann Ken sold 3.1k sh — Director ~$77k
2026-07-17INSIDERHerrmann Ken disposed of 3.1k sh Stock Option (Right to Buy) — Director
2026-07-08INSIDERRon-Bigger Shulamit sold 30.0k sh — Chief Operating Officer ~$838k
2026-07-08INSIDERCzibere Akos transacted 50.0k sh — Chief Medical Officer ~$248k
2026-07-08INSIDERRon-Bigger Shulamit sold 4.2k sh — Chief Operating Officer ~$121k
2026-07-08INSIDERCzibere Akos sold 14.8k sh — Chief Medical Officer ~$401k
2026-07-08INSIDERCzibere Akos sold 30.8k sh — Chief Medical Officer ~$862k
2026-07-08INSIDERCzibere Akos sold 4.4k sh — Chief Medical Officer ~$125k
2026-07-08INSIDERRon-Bigger Shulamit transacted 50.0k sh — Chief Operating Officer ~$183k
2026-07-08INSIDERRon-Bigger Shulamit sold 15.8k sh — Chief Operating Officer ~$429k
2026-07-08INSIDERRon-Bigger Shulamit disposed of 50.0k sh Stock Option (Right to Buy) — Chief Operating Officer
2026-07-08INSIDERCzibere Akos disposed of 50.0k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-04-15 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
2026-04-15 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
2026-04-15INSIDERGormley Glenn acquired 37.9k sh Stock Option (Right to Buy) — Director
2026-01-12 00:00 UTCINSIDER52 insider transactions — 2026-01 · net buy $114.3M 26 derivative
2026-01-12 00:00 UTCINSIDER52 insider transactions — 2026-01 · net buy $114.3M 26 derivative
2026-01-12INSIDERFoley Todd bought 232.9k sh — Director, 10% owner ~$4.19M
2026-01-12INSIDERGADICKE ANSBERT transacted 1.58M sh — 10% owner
2026-01-12INSIDERGADICKE ANSBERT transacted 5.91M sh — 10% owner
2026-01-12INSIDERGADICKE ANSBERT transacted 1.31M sh — 10% owner
2026-01-12INSIDERMPM BIOVENTURES 2018, L.P. bought 1.11M sh — 10% owner ~$20.03M
2026-01-12INSIDERMPM BIOVENTURES 2018, L.P. transacted 1.58M sh — 10% owner
2026-01-12INSIDERMPM BIOVENTURES 2018, L.P. transacted 5.91M sh — 10% owner
2026-01-12INSIDERMPM BIOVENTURES 2018, L.P. transacted 1.31M sh — 10% owner
2026-01-12INSIDERGADICKE ANSBERT bought 1.11M sh — 10% owner ~$20.03M
Showing the 40 most recent of 53 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage